All In Biotech

NDA 022468 · Acrotech Biopharma

Folotyn

Pralatrexate · Intravenous · Folate Analog Metabolic Inhibitor

NovelAccelerated approvalPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Oct 20, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2009

Sep 24, 2009

Approved uses

1

Original approval plus efficacy supplements

Registered trials

42

6 Phase 3, 7 recruiting

FAERS reports

650

603 serious, 164 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 16, 2026.

FOLOTYN is indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). This indication is approved under accelerated approval based on overall response rate [ see Clinical Studies (14) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). FOLOTYN is a dihydrofolate reductase inhibitor indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ( 1 )

Mechanism: Pralatrexate is a folate analog metabolic inhibitor that competitively inhibits dihydrofolate reductase. It is also a competitive inhibitor for polyglutamylation by the enzyme folylpolyglutamyl synthetase. This inhibition results in the depletion of thymidine and other biological molecules the synthesis of which depends on single carbon transfer.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Sep 24, 2009 Original approval · Type 1 - New Molecular Entity · priority review NovelAccelerated approvalOrphanLabelReviewLetter
2 products under this application
  • FOLOTYN · PRALATREXATE 20MG/ML (20MG/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
  • FOLOTYN · PRALATREXATE 40MG/2ML (20MG/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Pralatrexate" as an intervention, any sponsor and status, largest first.

All 42 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • malignant neoplasm progression118
  • stomatitis103
  • disease progression71
  • mucosal inflammation64
  • platelet count decreased57
  • pyrexia51
  • anaemia49
  • neutrophil count decreased42
  • drug ineffective41
  • febrile neutropenia39
  • neutropenia34
  • off label use33

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
201031
201133
201238
201337
201415
201524
201629
201724
201846
201943
202062
2021105
202259
202335
202424
202533
202612

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part B: Folotyn* (Pralatrexate*) · HCPCS J9307

2024 spending

$21.3M

Beneficiaries

137

1,459 claims

Per beneficiary

$155,281

2024 ASP limit $315.33 per unit

View as table
YearSpending
2020$21,673,585
2021$21,749,113
2022$20,225,398
2023$23,008,391
2024$21,273,530

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 28 on PubMed

Sponsor: Acrotech Biopharma

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.